Archives
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2018-07
-
Mutational Drivers and Drug Resistance in Myeloma Cell Lines
2026-07-07
This article reviews a comprehensive exome sequencing study of 30 human multiple myeloma cell lines, revealing key genetic mutations and pathways that contribute to tumor progression and drug resistance. The findings provide a robust framework for selecting relevant models and designing targeted interventions in hematological malignancy research.
-
Moesin as a Biomarker of Endothelial Injury in Sepsis: Insig
2026-07-07
The reference study identifies moesin (MSN) as a novel biomarker indicative of endothelial injury severity in sepsis, linking its serum levels to inflammatory and permeability changes. This finding advances our understanding of sepsis pathogenesis and offers a foundation for translational research into endothelial dysfunction.
-
Moesin as a Biomarker of Endothelial Injury in Sepsis Models
2026-07-06
Chen et al. (2021) demonstrate that moesin (MSN) is a promising biomarker for endothelial injury severity in sepsis. Their findings link MSN expression to both clinical severity and mechanistic pathways, providing new avenues for evaluating vascular dysfunction and supporting translational research in sepsis.
-
Applied Use of Anti-ROR1 Antibody (Zilovertamab) in Translat
2026-07-06
Leverage Anti-ROR1 Antibody (Zilovertamab) for precision inhibition of Wnt5a-induced ROR1 signaling in cancer and liver injury models. This article delivers actionable protocols, troubleshooting strategies, and cross-domain insights that distinguish APExBIO's antibody in advanced research workflows.
-
AP20187: Chemical Inducer of Dimerization for Precision Rese
2026-07-05
AP20187 empowers researchers with tunable, high-fidelity control over protein-protein interactions and signaling in conditional gene therapy and metabolic studies. Its robust solubility, validated in vivo efficacy, and unique ability to regulate fusion protein dimerization enable advanced experimental designs and streamlined troubleshooting.
-
BATF2-ATF3 Axis Drives Mitochondrial Dysfunction in IVDD Pro
2026-07-04
A recent study delineates how the BATF2-ATF3 transcriptional axis exacerbates intervertebral disc degeneration (IVDD) by destabilizing mitochondrial homeostasis in nucleus pulposus cells. This molecular insight suggests that targeting BATF2 or ATF3 could represent a novel strategy for IVDD intervention.
-
Gamma-linolenic Acid (GLA): Precision Modulator in Inflammat
2026-07-03
Explore the advanced role of Gamma-linolenic acid (GLA) as a precision modulator in anti-inflammatory and immune signaling research. This in-depth analysis reveals unique mechanistic insights, practical assay guidance, and new perspectives on its translational potential.
-
Intravitreal Metformin Reduces CNV and Retinal Degeneration
2026-07-03
Xiao et al. present evidence that intravitreal metformin suppresses choroidal neovascularization and protects against light-induced retinal degeneration in mouse models. The study demonstrates both anti-angiogenic and neuroprotective effects, suggesting metformin's potential as an accessible intervention for neovascular age-related macular degeneration (nAMD).
-
BCECF-AM for Live-Cell pH Imaging: Mechanistic Insights and
2026-07-02
Explore how BCECF-AM, a leading intracellular pH indicator, advances our understanding of plant autophagy and vacuolar acidification. This article reveals mechanistic details and practical protocols, offering fresh perspectives beyond standard assay guides.
-
FITC-Concanavalin A (ConA) Conjugate: Technical Lab Guidance
2026-07-02
FITC-Concanavalin A (ConA) Conjugate provides researchers with a direct, fluorescence-based tool for detecting α-D-glucose and α-D-mannose residues on cell surfaces using immunofluorescence or flow cytometry. It is intended for applications in carbohydrate detection within defined storage and application parameters, and is not suitable for non-glycan targets or protocols requiring extended reagent stability.
-
PLK1 Regulation of p31comet in Mitotic Checkpoint Disassembl
2026-07-01
This study defines the mechanistic role of PLK1 in phosphorylating p31comet, thereby suppressing its function in mitotic checkpoint complex (MCC) disassembly. The findings clarify how PLK1-mediated phosphorylation prevents premature checkpoint inactivation, with important implications for cell cycle research and targeted cancer therapeutics.
-
Marein Restores Chemosensitivity via ABCG2 Inhibition in Can
2026-07-01
The referenced study demonstrates that marein, a flavonoid from Coreopsis tinctoria, acts as a competitive inhibitor of the ABCG2 transporter, thereby restoring sensitivity to chemotherapeutics—including Mitoxantrone—in multidrug-resistant cancer cells. These findings provide a mechanistic basis for pairing ABCG2 inhibitors with established anticancer agents to counteract drug resistance in oncology research.
-
5-(N,N-dimethyl)-Amiloride Hydrochloride: Precision Control
2026-06-30
Explore how 5-(N,N-dimethyl)-Amiloride hydrochloride enables advanced, targeted research in endothelial ion transport and pH regulation. This article uniquely bridges detailed mechanism, assay design, and translational insight for vascular biology.
-
BAY-826: Potent Small Molecule Inhibitor for Retinal Researc
2026-06-30
BAY-826 empowers precise dissection of angiopoietin-PEDF pathways in retinal neuron survival, offering unparalleled selectivity and potency for neurovascular research. Explore optimized protocols, troubleshooting tactics, and comparative insights that set BAY-826 apart in experimental ophthalmology.
-
Oxaliplatin: Enhancing Preclinical Cancer Chemotherapy Model
2026-06-29
Oxaliplatin, a platinum-based chemotherapeutic agent from APExBIO, empowers researchers to dissect DNA damage-induced apoptosis and resistance in metastatic colorectal cancer therapy. This article translates cutting-edge genomic findings and robust experimental workflows into actionable strategies for optimizing Oxaliplatin use in preclinical and translational research.